帕罗西汀治疗90例卒中后抑郁患者有效性及安全性临床分析  

The efficacy and safety clinical analysis of paroxetine on the 90 post-stroke depression patients

作　　者：苗海锋[1] 石铸[2] 马荣[2] 李庆军[2] 刘玉华[1] 陈杭军[1] 

机构地区：[1]东莞市人民医院综合科一区,广东东莞523000 [2]东莞市人民医院神经内科,广东东莞523000

出　　处：《临床和实验医学杂志》2014年第4期271-274,共4页Journal of Clinical and Experimental Medicine

基　　金：东莞市科技基金资助项目;编号2008105150015

摘　　要：目的探讨帕罗西汀治疗卒中后抑郁的有效性及对神经功能恢复的疗效。方法将90例卒中后抑郁患者随机分为治疗组、对照组各45例;两组均给予卒中常规治疗,治疗组给予帕罗西汀联合常规脑血管病药物治疗,对照组给予常规脑血管病药物治疗;在治疗后1、4、8周用Hamilton抑郁量表(HAMD)、神经功能缺损量表(NIHSS)、日常生活能力(BI))及副作用量表(TESS)进行疗效评定和副作用评定。结果在治疗后8周,治疗组患者HAMD评分、NIHSS评分、Barthel评分分别与对照组比较,差异有统计学意义(P<0.05);治疗组与对照组TESS评分差异无统计学意义(P>0.05)。结论帕罗西汀有利于改善脑卒中后抑郁程度,安全性好。Objective To investigate the clinical efficacy and safety of paroxetine on the post - stroke depression patients. Methods 90 cases with post - stroke depression were randomly divided into treatment group and control group, 45 cases differently. The treatment group was treated with paroxetine and conventional cerebrovascular medicine. The control group was given conventional cerebrovascular medicine only. The efficacy and adverse events were assessed by HAMD, NIHSS, BI and TESS before and after treatment 1, 4, 8 weeks, respectively. Results Comparing the treatment group before and after, HAMD at week 4（ F = 10.47, P =0. 019）, at week 8（ F =56.64, P 〈0. 001 ） ; NIHSS at week4（F =16.23,P =0.037）, at weekS（F =24.52, P =0.011）. Barthelatweek4（F =15.64,P =0.032）, at weekS（F =27.12, P = 0. 009）. TESS was no significant difference on the rate of adverse events between the two groups （4.3 ± 1.7, 4.2 ± 1.6, P 〉 0.05 ）. Con- dusion Paroxetine was effective and safe antidepressant on the post - stroke depression patients.

关 键 词：帕罗西汀 卒中后抑郁 疗效 安全性 

分 类 号：R749.1[医药卫生—神经病学与精神病学]